Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Get Neurocrine Biosciences alerts:Get Our Latest Analysis on Neurocrine BiosciencesNeurocrine Biosciences Trading Down 2.7%Insider Transactions at Neurocrine BiosciencesShares of NBIX opened at $161.50 on Tuesday. Ruffer LLP acquired a new position in Neurocrine Biosciences in the 4th quarter valued at $2,479,000. Further ReadingReceive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.